Bobot Debuts as Public Company: Targeting RAS Pathway Malignancies
BridgeBio Oncology Therapeutics (BBOT) has officially launched on the Nasdaq Global Market under the ticker symbol “BBOT,” following a...
Jon Napitupulu
Tevogen Projects $1B Launch Revenue, $10-14B Over 5 Years
Tevogen Bio projects ambitious revenue figures for its oncology pipeline, forecasting $1 billion in its launch year and a...
Artelo Biosciences Gets European Patent Allowance for ART27.13 Formulation
Artelo Biosciences has secured a Notice of Allowance from the European Patent Office for its European patent application covering...
Kamada Gets FDA Nod for Houston Plasma Center
Kamada Ltd. has received FDA approval for its Houston plasma collection center to begin commercial sales of normal source...
Nxera Launches Proprietary Pipeline for Obesity and Weight Management
Nxera Pharma has unveiled an ambitious pipeline of next-generation obesity and metabolic disorder therapies, including a proprietary oral small-molecule...
CDT Equity Inc.: Conduit to Change Name
Conduit Pharmaceuticals, now rebranded as CDT Equity Inc., is shifting from a traditional pharmaceutical model to a lean, asset-centric...
Clearmind Medicine Gets IRB Approval for Alcohol Use Disorder Trial
Clearmind Medicine has secured Institutional Review Board (IRB) approval from Hadassah Medical Center in Jerusalem for its ongoing Phase...
Cho Plus & BARDA BioMAP: Filovirus Antibody Cell Lines
CHO Plus Secures BARDA Funding to Bolster Biodefense Manufacturing Capabilities CHO Plus, Inc. has been awarded up to $10.4...
Orchestra Biomed Raises $111M+ After Key Transactions
Orchestra Biomed Secures $111.2 Million in Funding, Signaling Confidence in Late-Stage Cardiovascular Therapies Orchestra Biomed has successfully closed a...
onco360® Selected as Specialty Pharmacy Partner for Lynozyfic™
Onco360 has secured a coveted spot as a national specialty pharmacy partner for Regeneron’s newly approved multiple myeloma therapy,...